Condition: Vulvar Diseases · HPV Infection · Vulvar HSIL · Sponsor: Frantz Viral Therapeutics, LLC
This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).
This description comes directly from the study's public registry record.
Mihaela Plesa · 440-255-1155 · fvtinfo@frantzgroup.com
Ahmad Bayat, MD · 301-956-2523
Always discuss trial participation with your own doctor first.
| Florida Gynecologic Oncology | Fort Myers, Florida, United States | Recruiting |
| Ascension St. Vincent | Indianapolis, Indiana, United States | Recruiting |
| Cleveland Clinic Fairview Hospital | Cleveland, Ohio, United States | Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| Hillcrest Hospital | Mayfield Heights, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06075264